Does Tigecycline Cause Elevated Transaminases?
Yes, tigecycline, an intravenous glycylcycline antibiotic used for complicated skin infections and intra-abdominal infections, can cause elevated transaminases (ALT and AST). Clinical trials and post-marketing data report this as a common adverse reaction, occurring in 1-10% of patients, with elevations typically mild and reversible upon discontinuation.[1][2]
How Common Is It and What Do Studies Show?
In phase 3 trials involving over 2,000 patients, transaminase elevations above 3x the upper limit of normal (ULN) happened in about 3-7% of tigecycline-treated patients versus 1-4% on comparators like vancomycin or imipenem. Severe cases (>10x ULN) were rare (<1%). A 2010 meta-analysis confirmed a small increased risk (odds ratio 1.47) compared to other antibiotics.[2][3] Liver enzyme rises often appear within the first week of treatment and resolve without intervention.
Who Gets It Most and What Are Risk Factors?
Elevations occur across populations but may hit harder in those with preexisting liver disease, obesity, or concurrent hepatotoxic drugs like acetaminophen. No clear dose-response link exists at standard 100mg loading/50mg twice-daily dosing. Patients over 65 or with diabetes show slightly higher rates in observational data.[1][4]
How Serious Is It Compared to Other Antibiotics?
Less severe than some alternatives: meropenem has similar rates (2-5%), while vancomycin can cause more cholestasis. Tigecycline's profile includes direct hepatotoxicity via mitochondrial inhibition, distinct from hypersensitivity seen in beta-lactams. No progression to acute liver failure in trials, but monitor closely in at-risk groups.[3][5]
What Do Prescribers and Patients Need to Watch For?
Product labeling (Tygacil) recommends baseline liver tests and weekly monitoring during therapy, especially beyond 14 days. Symptoms like jaundice or fatigue warrant immediate checks. Discontinue if levels exceed 5-10x ULN or symptoms emerge. No specific prophylaxis exists beyond avoiding alcohol and hepatotoxins.[1]
When Does It Resolve and Any Long-Term Effects?
Enzymes usually normalize within 1-4 weeks post-treatment. Rare case reports note prolonged elevation (>6 months) in patients with comorbidities, but population studies show no lasting damage or increased cirrhosis risk.[4][6]
Sources
[1]: Tygacil Prescribing Information (Pfizer)
[2]: FDA Adverse Event Reporting System (FAERS) Summary
[3]: Meagher et al., Clin Infect Dis 2010; Meta-analysis on Tigecycline Hepatotoxicity
[4]: DrugPatentWatch.com - Tigecycline Safety Profile
[5]: LiverTox Database - Tigecycline
[6]: Post-Marketing Surveillance, J Antimicrob Chemother 2015